Silex's existing license agreement with GLE (the Amended and Restated Technology Commercialisation and License Agreement) signed 2013, is an exclusive worldwide license for exploitation of the SILEX technology. The agreement provides for a perpetual royalty and further milestone payments if the SILEX technology is commercialised by GLE. In the event that the commercialisation activities cease in the US, it is likely that the Amended and Restated Technology Commercialisation and License Agreement will be terminated. Therefore, the future of the commercialisation program for the SILEX technology and the timing of any potential milestone payments and royalties under the License Agreement is highly uncertain.

Contact us

Registered Office:
Lucas Heights Science and Technology Centre New Illawarra Road
Lucas Heights NSW 2234
Australia

Postal Address:
PO Box 75
Menai Central NSW 2234
Australia


General Enquiries:
enquiries@silex.com.au

Investor Relations:
investor.relations@silex.com.au
Call: +61 2 9704 8888